 Bristol-Myers Squibb Co. said the U.S. Food and Drug Administration rejected its new drug application for its hepatitis C treatment in combination with other agents, pending the submission of additional information requested by the regulator.. The pharmaceutical company said its regulatory filing had focused on the hepatitis C treatment—called daclatasvir—in combination with another treatment called asunaprevir, which the Bristol-Myers withdrew in October. The company said that the FDA in a “complete response” letter requested...
  